💎 2025-2026 核心代表論文
Faculty-Led Research Achievements
Uncovering the untapped potential of furosemide in sepsis: Real-world evidence on coagulopathy and organ outcomes.
🔗
Hao-Yuan Hung
洪浩淵,
Chi-Hsiang Chung,
Chih-Chin Shih
施志勤,
Shiu-Jen Chen, Hsieh-Chou Huang, Wu-Chien Chien, and Chin-Chen Wu
SHOCK 2026; 66(4): 930–940
💡 研究亮點：
運用台灣健保資料庫 9,934 位敗血症患者的真實世界資料，發現早期使用 furosemide 與較低的瀰漫性血管內凝血（DIC）、輸血及心臟、呼吸與急性腎衰竭風險相關，支持其除利尿作用外，在敗血症凝血異常與器官保護上的潛在藥物再定位價值。
Coenzyme Q10 ameliorates obesity by promoting white adipose tissue browning and preserving mitochondrial dynamics in ovariectomized rats fed a high-fat diet. 🔗
Tong Pan, Shu-Ying Chen, Ching-Wen Kung, Hsuan-Yu Chen, Pao-Yun Cheng, Hsin-Hsueh Shen, Ing-Luen Shyu*, Yen-Mei Lee*李燕媚
Journal of Nutritional Biochemistry 2026; 149: 110187
💡 研究亮點：發現輔酶Q10 (CoQ10) 能透過促進白色脂肪褐變與維持粒線體動態，改善因切除卵巢並餵食高脂飲食大鼠的肥胖問題。
Neuroinflammation and immune microenvironment alterations following heat stroke: A transcriptomic perspective. 🔗
KN Chou, XJ Lu, HF Lai, YL Chiu, CC Shih施志勤
Computers in Biology and Medicine, 2025 Sep; 196(PtB): 110773
💡 研究亮點：透過轉錄組學視角，深入探討中暑後引發的神經性發炎與免疫微環境的改變，為中暑機轉提供新見解。
Therapeutic potential of butyrate against heat Stress-Induced intestinal damage, systemic inflammation, and multiple organ Dysfunction: Insights from in vitro and in vivo experiments. 🔗
HY Ke, MH Chen, CM Tsao, HP Hii, CW Kuo, SM Ka, CC Wu, CC Shih*施志勤
European Journal of Pharmacology, 2025 Jul; 999: 177710
💡 研究亮點：結合體內外實驗，證實丁酸鹽 (butyrate) 具有對抗熱緊迫引發的腸道損傷、全身性發炎及多重器官功能障礙的治療潛力。
Development of inhalable spray dried nalbuphine hydrochloride powders. 🔗
W Tai, HJ Wang, D Khanal, PTH Kwong, P Tang, CC Shih*施志勤, HK Chan*
International Journal of Pharmaceutics, 2025 Jul; 682: 125952
💡 研究亮點：成功開發出可供吸入的納布啡 (nalbuphine) 鹽酸鹽噴霧乾燥粉末，為鎮痛藥物提供新型給藥途徑。
Intrathecal injections of non-peptide oxytocin receptor agonists, WAY 267,464 and TC OT 39, induce significant anti-hyperalgesia in both male and female rats with inflammatory pain. 🔗
Lok-Hi Chow, Yuan-Hao Chen, Ying-Jie Chen, Pin-Chen Lin, and Eagle Yi-Kung Huang*黃翊恭
Iranian Journal of Basic Medical Sciences 2025; 28(9): 1212-1219
💡 研究亮點：【突破慢性疼痛治療的性別差異限制】 首度證實中樞脊髓內注射「非胜肽類催產素受體致效劑」，能有效克服女性體內特異性降解酶 (IRAP) 的阻礙，在兩性模型中皆展現不具性別差異的強效抗炎性痛覺過敏與觸發痛效果，具備極佳臨床應用潛力。
NKCC1 inhibition as a breakthrough in combating coagulopathy and boosting survival in LPS-induced DIC rat model. 🔗
Hung, H.Y.
洪浩淵,
C.C. Shih, M.H. Liao, S.J. Chen, H.C. Huang,
C.C. Wu*
吳錦楨
Eur. J. Pharmacol. 2025; 1008: 178348
💡 研究亮點：證實抑制NKCC1可作為對抗凝血功能異常的突破性策略，並能有效提升脂多醣(LPS)誘導的瀰漫性血管內凝血(DIC)大鼠模型的存活率。
Neuroprotective potential of isofraxidin: Alleviating parkinsonian symptoms, inflammation and microglial activation. 🔗
Wang, T. A., Li, S. Y., Fann, L. Y., Li, I. H., Liu, T. T., Hung, H. Y., Chang, C. W., Cheng, C. C., Huang, Y. C., Yu, P. Y., and Shih, J. H.*施睿琥
Journal of Central Nervous System Disease 2025; 17, 11795735241312661
💡 研究亮點：揭示異秦皮啶 (isofraxidin) 具備神經保護潛力，能有效緩解帕金森氏症狀、降低神經發炎並抑制微膠細胞的活化。